Maropost bolsters product leadership team to accelerate innovation and growth
21.5.2024 20:15:00 EEST | Business Wire | Press release
Maropost, the commerce software suite built for fast-growing commerce brands, announces two significant appointments to its senior leadership team: Tim Schulz joins as VP of Product, Commerce Cloud, and Alessandra "Alex" Jacques steps in as VP of Product, Marketing Cloud.
"I founded Maropost to disrupt a crowded market, and with Tim and Alex on board, we are aggressively pursuing that vision," said Maropost Chairman and CEO Ross Andrew Paquette. "We're building a single platform that puts fast-growing retailers in control of their customer journeys, from hyper-personalized marketing to in-store and online purchases through exceptional service.
"Brands will use Maropost to create and manage product catalogs, centrally design and deploy promotions across all their channels, build engaging storefronts, and deliver personalized shopping experiences from one data set, in one nerve center."
Paquette is confident Maropost will achieve this mission. "We're not just another player in the market; we're here to redefine it. Watch closely: We're about to show what's possible when ingenuity meets determination."
About the New Appointees
Alex Jacques brings deep product management expertise from her roles at Terminus and Cheetah Digital. A certified CSM and CSPO, she excels at leading highly functional scrum teams, managing multiple platforms, and driving customer experience strategies. Her marketing technology prowess will shape the future of Marketing Cloud.
Tim Schulz is a seasoned product and technology leader with a track record of delivering outstanding results. As Head of Product at Magento and VTEX, he built products that enabled mid-market and enterprise retailers to scale their businesses globally and respond to shifts in the industry. At BigCommerce, he led Product & Engineering and grew revenue to over $100 million ARR in 24 months while launching strategic partnerships with top tech companies, including Facebook, Twitter, Google, and Alibaba.
Tim was also a top 5% performer at Google, where he led global platform partnerships for Google Shopping and drove 40 full-cycle enterprise deals across product lines. At Maropost, Tim will direct the development of future commerce products.
"We're thrilled to welcome Alex and Tim to the Maropost team," said Sean Brady, COO and President of Maropost. "Their extensive product expertise, proven leadership, and passion for delivering exceptional customer experiences will help us realize our vision of a unified platform that helps them grow, scale, and drive real value from their marketing, commerce, and service efforts."
About Maropost
Only Maropost unites the commerce tools and insights growing brands need to engage customers and scale their business. Built on unified customer data and an enterprise-grade infrastructure, Maropost offers a complete, connected suite of marketing, merchandising and search, customer service, ecommerce, and retail solutions.
Since its founding in 2011, Maropost has made multiple appearances on Deloitte's Technology Fast 500 list and G2's leaderboard. A global company, Maropost proudly serves 5,000+ leading commerce brands across North America, Australia, and Europe, including Victoria Beckham, Sandro Paris, Untuckit, Scott Sports, James Perse, and Fujifilm.
Learn more at www.maropost.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521528910/en/
Contact information
Rob Wade
(888) 438-3152
press@maropost.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
